Gary Schwartz
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer (NCT02619669) | Gary Schwartz | 2017-04-20 |
| Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy (NCT00225758) | Gary Schwartz | 2006-01-01 |
Track Gary Schwartz automatically
Every clearance here is in the API, with alerts when new ones post.